Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Depreciation & Amortization (2016 - 2025)

Lineage Cell Therapeutics' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 5438.78% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, up 5438.78%, while the annual FY2025 figure was $2.7 million, 5438.78% up from the prior year.
  • Accumulated Depreciation & Amortization reached $2.7 million in Q4 2025 per LCTX's latest filing, up from $2.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $419.0 million in Q3 2023 to a low of $49000.0 in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $64.6 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 99.92% in 2021, then surged 88384.85% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $663000.0 in 2021, then fell by 12.22% to $582000.0 in 2022, then soared by 135.22% to $1.4 million in 2023, then crashed by 96.42% to $49000.0 in 2024, then soared by 5438.78% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Accumulated Depreciation & Amortization are $2.7 million (Q4 2025), $2.6 million (Q3 2025), and $2.4 million (Q2 2025).